MedTrace Logo

A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers

NCT00321945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 546

Last updated 2013-09-27

No results posted yet for this study

Summary

It is well known that atrial fibrillation (AF) and atrial flutter occur frequently after most types of cardiac surgeries.(1-4) Postoperative AF is associated with significant morbidity, longer hospital stay, and higher related costs. Currently, it is common procedure to premedicate patients with antiarrhythmic drugs for elective cardiac surgeries. Treatments such as beta blockers, Amiodarone, and electrical pacing are used to help prevent the morbidity associated with pot-operative AF.(5)

Renin-angiotensin system (RAS) activation may contribute to AF. Several clinical trials have suggested that inhibitors of this system may reduce the incidence of AF.(6-12) Patients with AF are known to have increased levels of angiotensin converting enzyme (ACE) and some types of angiotensin receptors.(13-15) Data from animal studies performed by our group suggest that cardiac ACE overexpression may lead to arrhythmic ion channel changes.(16;17) Although not studied in this group yet, it would be reasonable to conclude that the use of ACE inhibitors and angiotensin receptor blockers (ARBs) would decrease the incidence of AF in post-operative patients, too

Conditions

Interventions

PROCEDURE

ACE-Inhibitors and Angiotensin Receptor Blockers

Retrospective study - no intervention as part of study.

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Samuel C Dudley, Jr., MD, PhD · US Department of Veterans Affairs

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00321945 on ClinicalTrials.gov